Navigating the Expanding Treatment Landscape in Generalized Myasthenia Gravis

Summary

The discussion focuses on how clinicians can choose and adjust treatment for generalized myasthenia gravis (gMG) as the number of available therapies grows. The central message is that treatment should be individualized: disease severity and antibody status matter, but so do a patient’s needs, preferences, comorbidities, ability to access or administer treatment, costs, and insurance coverage.

Practical Approach to Choosing Treatment

The guest describes a decision process that includes:

• Confirming the diagnosis. Check for relevant antibodies, including acetylcholine receptor and MuSK antibodies, while interpreting results in context. Some tests, including LRP4, can produce false positives. Take a careful history of symptoms, triggers, and disease progression.
• Assessing the patient as a whole. Consider symptom severity, age, gender, pregnancy plans, other medical conditions, daily responsibilities, and how quickly improvement is needed.
• Matching treatment to practical circumstances. Ask whether the patient prefers oral medication, clinic-based infusions, or self-injection, and whether travel to an infusion center or home administration is feasible.
• Discussing cost and access early. Insurance approvals can take weeks and may require patients to try conventional treatments first. Cost can also determine which options a patient is willing to consider.
• Making the choice collaboratively. Explain the trade-offs among options and involve the patient in selecting a treatment approach.

Treatment Options and Trade-Offs

• Conventional treatments: Pyridostigmine may be sufficient initially for some patients. Prednisone can act quickly and is inexpensive, making it useful while discussing longer-term options or waiting for insurance approval, but prolonged use carries substantial side effects. Older immunosuppressants—including mycophenolate, azathioprine, and, less commonly, calcineurin inhibitors—remain options, although some take a long time to work and may require monitoring.
• FcRn inhibitors: The guest often considers these when a relatively rapid response is wanted and access is feasible. They may appeal to some patients, including women planning pregnancy, because conventional drugs can have pregnancy-related restrictions. However, safety information for newer therapies in pregnancy remains limited. Treatment schedules and routes vary.
• Complement inhibitors: These may be considered in severe disease or when a patient prefers a particular delivery method. They require attention to vaccination and infection-prevention procedures. Compared with FcRn inhibitors, the guest says there is less experience with how to stop or taper them.
• B-cell therapies: These can be effective but may take longer to work. The guest notes emerging research suggesting a potential benefit from starting some B-cell therapies earlier, but says further evidence is needed.
• Combining newer therapies: There is limited real-world evidence about using therapies from different classes together. The guest is cautious about FcRn inhibitors in patients taking other monoclonal antibodies, since possible effects on those drugs have not been well studied. Insurance coverage may also limit combination treatment.

Defining Success and Adjusting Therapy

The treatment goal remains the same regardless of the drug: achieve the patient’s best possible disease control with the fewest side effects. Clinicians should account for how long a medication may take to work and discuss expectations with patients, who may want to switch if improvement is not apparent. A lack of response does not necessarily mean another drug in the same class will also fail, but the best sequencing strategy remains uncertain.

Prednisone should generally be reduced as much as possible. The guest’s ideal target is no prednisone; a dose around 7.5 mg daily or less is described as preferable when possible, though some patients need more. Brief, patient-supervised increases during flares or predictable periods of worsening may sometimes be considered.

For long-term prednisone use, the discussion highlights monitoring for bone loss, glucose problems, blood-pressure changes, and other side effects. Elevated white blood cell counts also need careful interpretation because they can occur with prednisone even without infection.

Acute Worsening and Myasthenic Crisis

For now, hospitals generally rely on established rescue treatments such as plasma exchange and IVIG, partly because newer therapies can be expensive or unavailable in hospital formularies. Studies and case reports are examining newer agents for acute exacerbations, but the speakers note that more results are needed before their role is clear.

Research Needs and Thymectomy

The speakers call for more evidence to guide treatment selection and sequencing. They express interest in platform trials that compare or combine therapies, further study of B-cell treatments aimed at underlying disease mechanisms, and early research into CAR T-cell therapy. They caution that long-term outcomes for emerging approaches are not yet known.

Thymectomy remains an important treatment consideration for appropriate patients. The guest says she considers it especially for patients in a suitable age group and uses medical therapy to help prepare them for surgery. The speakers also describe patients who have had substantial improvement after thymectomy, while acknowledging that some still need medication.

Speakers and Sources Featured

• Pritikanta Paul, MD, MBBS — Host; associate professor in the neuromuscular division at the UCSF Department of Neurology.
• Miriam Freimer, MD — Guest; professor in the Department of Neurology at The Ohio State University.
• Neuromuscular Insights — Program presented by NeurologyLive and the UCSF Department of Neurology.